Australia-based research overview for semaglutide — its GLP-1 receptor profile, structural identity, and expected analytical documentation.
Semaglutide is a long-acting GLP-1 receptor agonist that has become one of the most extensively published research peptides in the Australia. Originating from native GLP-1, the molecule was engineered with substitutions and a C18 fatty diacid linker that together extend its half-life to roughly one week and stabilize it against DPP-4 cleavage.
Structural identity
- 31-amino-acid GLP-1 analog
- Aib substitution at position 8 (DPP-4 resistance)
- C18 diacid spacer linked at Lys26 for albumin binding
- Average mass approximately 4113.6 Da
What a verified COA shows
- ≥98% HPLC purity
- LC-MS confirmed mass within ±0.5 Da
- Counterion identity and content
- Endotoxin per laboratory method
- Batch ID + synthesis date traceable to lot record
Research use only. Absorb Labs supplies materials strictly for in vitro and laboratory research. Nothing in this article constitutes medical, therapeutic, or dosage advice for human or animal use.
